(PharmaNewsWire.Com, October 28, 2017 ) Migraine is a common neurological disorder worldwide, which affects 12 to 14.7% of the population. Hence, with the increasing global population, particularly female population who are more prone to have a migraine, the market for the drugs will likely rise at a steady pace. A variety of drugs have been specifically designed for migraine treatment. Also, the launch of new drugs in market and increased focus on drug development by key players is expected to boost the margarine drugs market in the coming years. The above findings have been briefly discussed in a new study added to the vast portfolio of Market Research Hub (MRH), with the title of “Migraine Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025”. This research study provides a holistic perspective on market growth throughout the forecast period of 2017 to 2025 in terms of revenue estimates (in US$ Million) across different geographies, which include North America, the Middle East and Africa (MEA), Europe, Asia Pacific and Latin America.
Most people who suffer from migraine get headache that may occur with symptoms such as nausea, symptoms such as nausea, difficulty in speaking, vomiting, or increased sensitivity. Excessive consumption of alcohol and increase in consumption of oral contraceptives significantly increases the number of migraine disorder cases. There is wide range of treatment available to cure migraine, but therapeutic agents such as anti-inflammatory drugs (NSAIDs), botulinum toxin, topiramate and other drugs are used to cure migraine. Analysts have identified that the global migraine drugs market will likely expand at a lackluster CAGR of 3.5% during the period between 2017 and 2025 to become worth US$3.72 bn by 2025 from US$2.72 bn in 2016.
Firstly, the market overview section of the study highlights comprehensive view of the global migraine drugs market, including a market snapshot that provides overall information of various segments and sub-segments. The market can be segmented by type of therapeutic class of drugs involved in the treatment, route of administration, distribution channel and by region. Depending upon the available treatments, the global market for migraine drugs can be divided into abortive treatment and prophylactic treatment. It has been analyzed that abortive treatment segment is projected to hold dominant share of global migraine drugs market while prophylactic treatment segment is likely to register steady growth during the forecast period.
Based on the distribution channel, the global migraine drugs market is segmented into retail pharmacies, hospital pharmacies and others. On the basis of route of administration, the study covers Oral, Injectable and others (Nasal Spray, Transdermal Patch, etc.) In terms of geography, North America presently holds a dominant share in the market and anticipated to retain its dominance because of the higher allocations on healthcare and availability of specialty migraine drugs.
At last, the study concludes with an important section of competitive landscape which highlights the key players active in the market. Key companies profiled in the report include AstraZeneca Plc., Valeant Pharmaceutical International, Inc., Allergan Plc., Janssen Pharmaceutical Company (Johnson & Johnson), Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Endo Pharmaceuticals Inc., Eli Lilly & Co. Novartis AG, Merck & Co., Inc., Zosano Pharma Corporation, Alder BioPharmaceuticals Inc., and others.
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
